Efficacy of histaminergic drugs in experimental motion sickness

Journal of Vestibular Research: Equilibrium and Orientation

Volumn 17, Issue 5-6, 2007, Pages 313-321

  Matsnev, E I ^a   Sigaleva, E E ^a  

^a INSTITUTE OF BIOMEDICAL PROBLEMS   (Russian Federation)

Author keywords

Betahistine dihydrochloride; Coriolis stimulation; Histaminergic system; Motion sickness; Motion sickness treatment

Indexed keywords

BETAHISTINE; PLACEBO;

ACCELERATION; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; CORIOLIS PHENOMENON; DISEASE PREDISPOSITION; DRUG EFFICACY; EXPERIMENTAL MODEL; EYE MOVEMENT CONTROL; EYE TRACKING; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MOTION SICKNESS; NORMAL HUMAN; NYSTAGMUS; PRIORITY JOURNAL; PROVOCATION TEST; RECOMMENDED DRUG DOSE; ROTATION; SACCADIC EYE MOVEMENT; SENSATION; VELOCITY; VOLUNTEER;

ADOLESCENT; ADULT; BETAHISTINE; CORIOLIS FORCE; HISTAMINE AGENTS; HUMANS; MALE; MOTION SICKNESS; NYSTAGMUS, PATHOLOGIC; ROTATION; VESTIBULAR DISEASES;

EID: 47949096098     PISSN: 09574271     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. J.M. Bekkers, Enhancement by histamine of receptors synaptic transmission in the hippocampus, Science 261 (1993), 104-106.
2. T. Betts, D. Harris and E. Gadd, The effects of two anti-vertigo drugs (betahistine and prochlorperazine) on driving skills, Br J Clin Pharmacol 32 (1987), 131-135.
3. H.L. Borison and R. Borison, Motion sickness reflex arc by-passes the area postrema in cats, Exp Neurol 92 (1986), 723-727.
4. T.H. Brandt, Vertigo: multisensory syndromes. London: Springer -Verlag, 1991, 1-24.
5. M.L. Bouthenet, M. Ruat, N. Sales et al., A detailed mapping of histamine H1 receptors in guinea-pig central nervous system established by autoradiography with (I125) idobolpyramine, Neuroscience 26 (1988), 553-600.
6. A.J. Fisher and L.W van Elferen, Betahistine in the treatment of paroxysmal attacks of vertigo: A double-blind investigation, JDR 10 (1985), 9.
7. C.R. Ganellin, Chemistry and structure-activity relationships of drug acting at histamine receptors, in: Pharmacology of histamine receptors, C.R. Ganellin and M.E. Parsons eds., Wright PSG, Bristol, London, Boston, 1982, p. 10.
8. C.R. Gordon, I. Doweck, Z. Nachum et al., Evaluation of betahistine for the prevention of seaseckness: effect on vestibular function, psychomotor performance and efficacy at sea, J Vest Res 13(2-3) (2003), 103-111.
9. A. Graybiel, C.D. Wood, E.F. Miller and D.B. Cramer, Diagnostic Criteria for Grading the Severity of Acute Motion Sickness, Aerospace Medicine (May 1968), 453-455.
10. A. Graybiel, C.D. Wood, J. Knepton, J.P. Hiche and G.F. Perkins, Human assay of antimotion sickness drugs, Aviat Space Environ Med 46(9) (1975), 1107-1118.
11. G.M. Halmagyi, Vertigo and vestibular disorders, in: Drug therapy in neurology, J. Eadie, ed., Edinburgh: Churchille Livingstone, 1992, pp. 182-195.
12. S. Jeck-Thole and W. Wagner, Betahistine. A Retrospective Synopsis of Safety Data, Drug Safety 29(11) (2006), 1049-1059.
13. H. Kingma, M. Bonink, A. Meulenbroeks and H. Konijnenberg, Dose-dependent effect of betahistine on the vestibuloocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo, Acta Otolaryngol 117(5) (Sep. 1997), 641-646.
14. E.B. Kirsten and J.N. Sharma, Microiontophoresis of acetylcholine, histamine and their antagonists on neurons in the medial and lateral vestibular nuclei of the cat, Neuropharmacology 15 (1976), 743-753.
15. G.W. Knox, D. Woodard, W. Chelen et al., Phenytoin for Motion Sickness: Clinical Evaluation, Laryngoscope 104 (1994), 935-939.
16. M. Lacour, Histamine, vestibular function and vestibular compensation. Paris: Elsevier Paris, 1998, 55.
17. M. Lacour and O. Sterkers, Histamine and Betahistine in the Treatment of vertigo. Elucidation of Mechanisms of Action, CNS Drugs 15(11) (2001), 853-870.
18. E.A Laurikainen, J.M. Miller, A.L. Nuttall et al., The vascular mechanism of action of betahistine in the inner ear of the guinea pig, Eur Arch Otorhinolaryngol 255 (1988), 119-123.
19. E.A. Laurikainen, J.M. Miller, A.L. Nuttall et al., The vascular mechanism of action of betahistine in the inner ear of the guinea pig, Eur Arch Otorhinolaryngol 255 (1998), 119-123.
20. E.A. Laurikainen, J.M. Miller, A.L. Nuttall et al., Betahistine-induced vascular effects in the rat cochlea, Am J Otol 14 (Jan. 1993), 24-30.
21. J.S. Lin, Systeme histaminergique central et etats de vigilance ches le chat thesis. Lyon: These Doct. Sciences, Universite Claude Bernard Lyon I, 1994.
22. T. Matsunaga and N. Takeda, Motion sickness, in: Histaminergic neurons: morphology and function, T. Watanabe and H. Wada, eds, Boca Raton: CRC Press, 1991, pp. 315-322.
23. E.I. Matsnev, Angular acceleration, in: Space Biology and Medicine. III. "Human in spaceflight, Book 2, Charter 15. Joint US. Russian Publication, eds, A.E. Nikogossian, S. Mohler, O. Gazenko, A.Grigoriev. American Institute Aeronautics and Astronautics., Reston, V.A., 1996, pp. 333-348.
24. W.K. Oosterveld, Effect of betahistine dihydrochloride on induced vestibular nystagmus: a double blind study, Clin Otolaryngol Allied Sci 12(2) (Apr. 1987), 131-135.
25. S.V. Peppard, Effect of drug therapy on compensation from vestibular injury, Laryngoscope 96 (1986), 878-898.
26. K.D. Phelan, J. Nakamura and J.P. Gallagher, Histamine depolarizes rat medial vestibular nucleus neurons recorded intracellularly in vitro, Neurosci Lett 109 (1990), 287-292.
27. O. Rascol, T.C. Hain, C. Brefel et al., Antivertigo medications and drug-induced vertigo, Drugs 50 (1995), 777-791.
28. M.F. Reschke, Statistical Prediction of Space Motion Sickness, in: Motion and Space Sickness, CRC Press, Boca Raton, Fla., 1990, pp. 263-316.
29. J.T. Reason and J.J. Brand, Motion sickness, New York; Academic Press, 1975.
30. J.C. Schwartz, eds, Frontiers in histamine research, Plenum Press. Oxford, New York, 1986, pp. 119-130.
31. J.C. Schwartz, Histaminergic mechanisms in brain, Annu Rev Pharmacol Toxicol 17 (1997), 325-39.
32. H.W.M. Steinbusch and A.N. Mulder, Localization and projections of histamine immunoreactive neurons in the central nervous system of the rat, in: Pharmacology of histamine receptors, C.R. Ganellin and M.E. Parsons, eds., Wright PSG, Bristol, London, Boston, 1982.
33. F. Suga and J.B. Snow, Cochlear blood flow in response to vasodilatation drugs and some related agents, Laryngoscope 79 (1969), 1956-1979.
34. N. Takeda, M. Morita, T. Kubo et al., Histaminergic projection from the posterior hypothalamus to the medial vestibular nucleus of rats and its relation to motion sickness, in: The vestibular system: neurophysiologic and clinical research, M.D. Graham and J.L. Kemink, eds, New York: Raven Press., 1978, 571, p. 80.
35. N. Takeda, M. Morita, S. Hasegawa, A. Horii, T. Kubo and T. Matsunaga, Neuropharmacology of Motion Sickness and Emesis. A review, Acta Otolaryngol (Stockh.) 50 (1993), 10-15.
36. B. Tighilet, J. Leonard and M. Lacour, Betahistine dihydrochloride treatment facilitates vestibular compensation in the cat, Journal of Vestibular Research 5 (1995), 53-66.
37. B. Tighilet, S. Trottier, C. Mourre et al., Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms, European Journal of Pharmacology 446 (2002), 63-73.
38. H. Timmerman, Histamine agonists and antagonists, Acta Otolaryngol (Stockh) 479(suppl) (1991), 5-11.
39. M. Tomita, F. Goton, T. Sato et al., Comparative responses of the carotid and vertebral arterial systems of the rhesus monkeys to betahistine, Stroke 9 (1978), 382-387.
40. J.J. Wang and M.B. Dutia, Effects of histamine and betahistine on rat medial vestibular nucleus neurones: possible mechanism of action of anti-histaminergic drugs in vertigo and motion sickness, Exp Brain Res 105(1) (1995), 18-24.
41. R.E. West, A. Zweig, N.Y. Shih et al., Identification of two H3 - histamine receptor subtypes, Mol Pharmacol 38 (1990), 610-613.